Business Standard Q3 Preview: Strong domestic sales set to lift pharma revenues by up to 11%
Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth
Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth